Johnson & Johnson reported Q4 FY 2015 earnings of $1.44 per share (versus $1.27 in Q4 FY 2014), beating analysts' consensus of $1.42.
The company's quarterly revenues amounted to $17.811 bln (-2.4% y/y), generally in line with consensus estimate of $17.856 bln.
The company also issued guidance for FY 2016, projecting EPS of $6.43-6.58 (versus analysts' consensus of $6.40) and revenues of $70.8-71.5 bln (versus analysts' consensus of $71.99 bln).
JNJ rose to $96.75 (+0.36%) in pre-market trading.